FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 196, Issue 4, 2017, Pages 438-446

  Lipson, David A ^a,b   Barnacle, Helen ^c   Birk, Ruby ^c   Brealey, Noushin ^c   Locantore, Nicholas ^a   Lomas, David A ^d   Ludwig Sengpiel, Andrea ^e   Mohindra, Rajat ^c   Tabberer, Maggie ^c   Zhu, Chang Qing ^c   Pascoe, Steven J ^f  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e KLB Health Research   (Germany)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Chronic obstructive pulmonary disease; Health related quality of life; Lung function; Single inhaler triple therapy

Indexed keywords

BUDESONIDE; FLUTICASONE FUROATE; FORMOTEROL; PLACEBO; UMECLIDINIUM; VILANTEROL; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; BRONCHODILATING AGENT; CHLOROBENZENE; FORMOTEROL FUMARATE; QUINUCLIDINE DERIVATIVE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; RISK REDUCTION; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ANDROSTADIENES; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; BUDESONIDE; CHLOROBENZENES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; FORMOTEROL FUMARATE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINUCLIDINES;

EID: 85028428746     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201703-0449OC     Document Type: Article

References (21)

1. Wurst KE, Punekar YS, Shukla A. Treatment evolution after COPD diagnosis in the UK primary care setting. PLoS One 2014;9:e105296.
2. Simeone JC, Luthra R, Kaila S, Pan X, Bhagnani TD, Liu J, Wilcox TK. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis 2016;12:73-83.
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD 2017 global strategy for the diagnosis, management and prevention of COPD [accessed 2016 Dec 11]. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/
4. Siler TM, Kerwin E, Tombs L, Fahy WA, Naya I. Triple therapy of umeclidinium 1 inhaled corticosteroids/long-acting beta2 agonists for patients with COPD: pooled results of randomized placebo-controlled trials. Pulm Ther 2016;2: 43-58.
5. Lomas D, Lipson D, Barnacle H, Birk R, Brealey N, Zhu CQ, Tabberer M. Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: results of the FULFIL trial [abstract]. Eur Respir J 2016;48(Suppl 60):PA4629.
6. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26: 319-338.
7. Goyal N, Beerahee M, Kalberg C, Church A, Kilbride S, Mehta R. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet 2014;53:637-648.
8. Siederer S, Allen A, Yang S. Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in subjects with chronic obstructive pulmonary disease. Eur J Drug Metab Pharmacokinet 2016;41:743-758.
9. Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. Respir Med 2015;109:1155-1163.
10. Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM. Fluticasone furoate/vilanterol (100/25; 200/25 mg) improves lung function in COPD: a randomised trial. Respir Med 2013; 107:550-559.
11. Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C. A randomised trial of fluticasone furoate/vilanterol (50/25 mg; 100/25 mg) on lung function in COPD. Respir Med 2013;107:560-569.
12. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009;69:549-565.
13. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008;68:1975-2000.
14. 2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016;388:963-973.
15. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1:210-223.
16. Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 2012;106: 257-268.
17. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE; SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016;387:1817-1826.
18. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016;374:2222-2234.
19. Chrystyn H, van der Palen J, Sharma R, Barnes N, Delafont B, Mahajan A, Thomas M. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med 2017; 27:22.
20. Horsley MG, Bailie GR. Risk factors for inadequate use of pressurized aerosol inhalers. J Clin Pharm Ther 1988;13:139-143.
21. De Blaquiere P, Christensen DB, Carter WB, Martin TR. Use and misuse of metered-dose inhalers by patients with chronic lung disease. A controlled, randomized trial of two instruction methods. Am Rev Respir Dis 1989;140:910-916.